Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03881059 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT03881059 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 203 participants.
The verdict
NCT03881059, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily \[QD\]) at Week 16 in the treatment of participants with active PsA.
Interventions
- DRUG Ustekinumab
- OTHER BMS-986165 Placebo
- DRUG BMS-986165 Dose A
- DRUG BMS-986165 Dose B
- OTHER Ustekinumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03881059
The ClinicalTrials.gov registry entry for NCT03881059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ustekinumab is the first listed.
NCT03881059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03881059 about?
NCT03881059 is a clinical study titled "Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)". The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily \[QD\]) at Week 16 in the treatment of participants with active PsA.
What is the current status of trial NCT03881059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2019-04-01. Estimated completion is 2021-01-27.
What interventions are being tested in trial NCT03881059?
The interventions under investigation include: Ustekinumab (DRUG), BMS-986165 Placebo (OTHER), BMS-986165 Dose A (DRUG), BMS-986165 Dose B (DRUG), Ustekinumab Placebo (OTHER).
Who is sponsoring clinical trial NCT03881059?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.